Skip to main content
Erschienen in: Journal of Neurology 12/2015

01.12.2015 | Original Communication

Motor onset and diagnosis in Huntington disease using the diagnostic confidence level

verfasst von: Dawei Liu, Jeffrey D. Long, Ying Zhang, Lynn A. Raymond, Karen Marder, Anne Rosser, Elizabeth A. McCusker, James A. Mills, Jane S. Paulsen, The PREDICT-HD Investigators and Coordinators of the Huntington Study Group

Erschienen in: Journal of Neurology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Huntington disease (HD) is a neurodegenerative disorder characterized by motor dysfunction, cognitive deterioration, and psychiatric symptoms, with progressive motor impairments being a prominent feature. The primary objectives of this study are to delineate the disease course of motor function in HD, to provide estimates of the onset of motor impairments and motor diagnosis, and to examine the effects of genetic and demographic variables on the progression of motor impairments. Data from an international multisite, longitudinal observational study of 905 prodromal HD participants with cytosine–adenine–guanine (CAG) repeats of at least 36 and with at least two visits during the followup period from 2001 to 2012 was examined for changes in the diagnostic confidence level from the Unified Huntington’s Disease Rating Scale. HD progression from unimpaired to impaired motor function, as well as the progression from motor impairment to diagnosis, was associated with the linear effect of age and CAG repeat length. Specifically, for every 1-year increase in age, the risk of transition in diagnostic confidence level increased by 11 % (95 % CI 7–15 %) and for one repeat length increase in CAG, the risk of transition in diagnostic confidence level increased by 47 % (95 % CI 27–69 %). Findings show that CAG repeat length and age increased the likelihood of the first onset of motor impairment as well as the age at diagnosis. Results suggest that more accurate estimates of HD onset age can be obtained by incorporating the current status of diagnostic confidence level into predictive models.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983. doi:10.1016/0092-8674(93)90585-E CrossRef Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983. doi:10.​1016/​0092-8674(93)90585-E CrossRef
6.
Zurück zum Zitat Louis ED, Lee P, Quinn L, Marder K (1999) Dystonia in Huntington’s disease: prevalence and clinical characteristics. Mov Disord 14:95–101CrossRefPubMed Louis ED, Lee P, Quinn L, Marder K (1999) Dystonia in Huntington’s disease: prevalence and clinical characteristics. Mov Disord 14:95–101CrossRefPubMed
8.
Zurück zum Zitat Garcia Ruiz PJ, Hernandez J, Cantarero S, Bartolome M, Sanchez Bernardos V, Garcia de Yebenez J (2002) Bradykinesia in Huntington’s disease. A prospective, follow-up study. J Neurol 249:437–440. doi:10.1007/s004150200035 CrossRefPubMed Garcia Ruiz PJ, Hernandez J, Cantarero S, Bartolome M, Sanchez Bernardos V, Garcia de Yebenez J (2002) Bradykinesia in Huntington’s disease. A prospective, follow-up study. J Neurol 249:437–440. doi:10.​1007/​s004150200035 CrossRefPubMed
9.
10.
Zurück zum Zitat Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2013) Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 5:12. doi:10.3389/fnagi.2013.00012 PubMedCentralCrossRefPubMed Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2013) Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 5:12. doi:10.​3389/​fnagi.​2013.​00012 PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2009) Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study. Mov Disord 24:1763–1772. doi:10.1002/mds.22601 PubMedCentralCrossRefPubMed Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2009) Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study. Mov Disord 24:1763–1772. doi:10.​1002/​mds.​22601 PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, Graham RK, Hayden MR (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 4:398–403. doi:10.1038/ng0893-398 CrossRefPubMed Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, Graham RK, Hayden MR (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 4:398–403. doi:10.​1038/​ng0893-398 CrossRefPubMed
13.
Zurück zum Zitat Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA (1993) Correlation between the onset age of Huntington’s disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 2:1547–1549. doi:10.1093/hmg/2.10.1547 CrossRefPubMed Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA (1993) Correlation between the onset age of Huntington’s disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 2:1547–1549. doi:10.​1093/​hmg/​2.​10.​1547 CrossRefPubMed
14.
Zurück zum Zitat Lucotte G, Turpin JC, Riess O, Epplen JT, Siedlaczk I, Loirat F, Hazout S (1995) Confidence intervals for predicted age of onset, given the size of (CAG)n repeat, in Huntington’s disease. Hum Genet 95:231–232. doi:10.1007/BF00209410 CrossRefPubMed Lucotte G, Turpin JC, Riess O, Epplen JT, Siedlaczk I, Loirat F, Hazout S (1995) Confidence intervals for predicted age of onset, given the size of (CAG)n repeat, in Huntington’s disease. Hum Genet 95:231–232. doi:10.​1007/​BF00209410 CrossRefPubMed
17.
Zurück zum Zitat Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B:397–408. doi:10.1002/ajmg.b.30992 PubMedCentralPubMed Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B:397–408. doi:10.​1002/​ajmg.​b.​30992 PubMedCentralPubMed
18.
Zurück zum Zitat Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA, Cardon LR, Housman DE, Wexler NS (2007) Replication of twelve association studies for Huntington’s disease residual age of onset in large Venezuelan kindreds. J Med Genet 44:44–50. doi:10.1136/jmg.2006.045153 PubMedCentralCrossRefPubMed Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA, Cardon LR, Housman DE, Wexler NS (2007) Replication of twelve association studies for Huntington’s disease residual age of onset in large Venezuelan kindreds. J Med Genet 44:44–50. doi:10.​1136/​jmg.​2006.​045153 PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880. doi:10.1136/jnnp.2007.128728 PubMedCentralCrossRefPubMed Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880. doi:10.​1136/​jnnp.​2007.​128728 PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, Nance MA, Erwin CJ, Westervelt HJ, Harrington DL, Bockholt HJ, Zhang Y, McCusker EA, Chiu EM, Panegyres PK, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78. doi:10.3389/fnagi.2014.00078 PubMedCentralCrossRefPubMed Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, Nance MA, Erwin CJ, Westervelt HJ, Harrington DL, Bockholt HJ, Zhang Y, McCusker EA, Chiu EM, Panegyres PK, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78. doi:10.​3389/​fnagi.​2014.​00078 PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E, Predict-HD Investigators of the Huntington Study Group (2006) Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 63:883–890. doi:10.1001/archneur.63.6.883 CrossRefPubMed Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E, Predict-HD Investigators of the Huntington Study Group (2006) Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 63:883–890. doi:10.​1001/​archneur.​63.​6.​883 CrossRefPubMed
23.
Zurück zum Zitat Warner JP, Barron LH, Brock DJ (1993) A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington’s disease chromosomes. Mol Cell Probes 7:235–239. doi:10.1006/mcpr.1993.1034 CrossRefPubMed Warner JP, Barron LH, Brock DJ (1993) A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington’s disease chromosomes. Mol Cell Probes 7:235–239. doi:10.​1006/​mcpr.​1993.​1034 CrossRefPubMed
25.
Zurück zum Zitat Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H (2005) Interrater agreement in the assessment of motor manifestations of Huntington’s disease. Mov Disord 20:293–297. doi:10.1002/mds.20332 CrossRefPubMed Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H (2005) Interrater agreement in the assessment of motor manifestations of Huntington’s disease. Mov Disord 20:293–297. doi:10.​1002/​mds.​20332 CrossRefPubMed
27.
Zurück zum Zitat Zucchini W, MacDonald IL (2009) Hidden Markov models for time series : an introduction using R. CRC Press, Boca RatonCrossRef Zucchini W, MacDonald IL (2009) Hidden Markov models for time series : an introduction using R. CRC Press, Boca RatonCrossRef
29.
Zurück zum Zitat Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59:16–22PubMedCentralPubMed Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59:16–22PubMedCentralPubMed
30.
Zurück zum Zitat Sequeiros J, Ramos EM, Cerqueira J, Costa MC, Sousa A, Pinto-Basto J, Alonso I (2010) Large normal and reduced penetrance alleles in Huntington disease: instability in families and frequency at the laboratory, at the clinic and in the population. Clin Genet 78:381–387. doi:10.1111/j.1399-0004.2010.01388.x CrossRefPubMed Sequeiros J, Ramos EM, Cerqueira J, Costa MC, Sousa A, Pinto-Basto J, Alonso I (2010) Large normal and reduced penetrance alleles in Huntington disease: instability in families and frequency at the laboratory, at the clinic and in the population. Clin Genet 78:381–387. doi:10.​1111/​j.​1399-0004.​2010.​01388.​x CrossRefPubMed
Metadaten
Titel
Motor onset and diagnosis in Huntington disease using the diagnostic confidence level
verfasst von
Dawei Liu
Jeffrey D. Long
Ying Zhang
Lynn A. Raymond
Karen Marder
Anne Rosser
Elizabeth A. McCusker
James A. Mills
Jane S. Paulsen
The PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 12/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7900-7

Weitere Artikel der Ausgabe 12/2015

Journal of Neurology 12/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.